我們已在上線! 進一步了解
REVBW圖示

Revelation Biosciences Warrant

0.0052 USD
-0.0013
20%
收盤時 已更新 10月16日 下午4:00 EDT
1天
-20%
5天
-27.78%
1個月
-42.22%
3個月
-48%
6個月
-44.09%
今年迄今
-35.8%
1年
-58.73%
5年
-98.97%
10年
-98%
 

關於: Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.

員工: 9

新聞

正面
中性
負面
市場情緒 3個月
正面 0%
中性 0%
負面 0%

我們尚未收到任何關於REVBW的最新新聞文章。

價格圖表採用Lightweight Charts™實作